癌症患者血浆PAI-1浓度变化  

The plasma level of PAI-1 in normal group and cancer groups

作　　者：王宇[1] 肖英红[1] 何成彦[2] 王楠[1] 冯学超[1] 

机构地区：[1]东北师范大学膜通道实验室,吉林长春130024 [2]吉林大学中日联谊医院,吉林长春130033

出　　处：《中国实验诊断学》2010年第4期536-537,共2页Chinese Journal of Laboratory Diagnosis

基　　金：国家自然科学基金资助项目(30770493)

摘　　要：目的测定多种恶性肿瘤患者血浆中纤溶酶原激活物抑制剂1(Plasminogen activator inhibitor-1,PAI-1)浓度变化情况,探讨PAI-1血浆含量变化作为恶性肿瘤诊断中的作用。方法收集乳腺癌、肺癌、喉癌血液标本各40例,并以正常人血液标本作对照,用ELISA法检测肿瘤患者及正常对照组血浆中PAI-1的含量,并比较其差异。结果与正常对照组(9.84±4.66 ng/ml)相比,乳腺癌(21.49±10.54 ng/ml),肺癌(15.10±8.55 ng/ml),喉癌(14.03±7.14 ng/ml)患者血浆中PAI-1含量均明显升高,其中乳腺癌组与正常组相比差异极为显著(P<0.01)。结论血浆中PAI-1的浓度升高可作为肿瘤诊断辅助指标,PAI-1可作为肿瘤治疗潜在靶位。Objective to explore the variation of PAI-1 concentration in blood plasma between normal group and cancer groups. Methods assay the plasma PAI-1 level in both cancer groups and normal group by ELISA. Results PAI-1 levels in plasma of breast cancer groups（21.49±10.54 ng/ml）, lung breast cancer groups（ 15.10 ± 8.55 ng/ml） and larynx cancer groups （14.03 ± 7.14 ng/ml）were higher than that of normal group（9.84 ±4.66 ng/ml）, particularly, the PAI-1 concentration in breast cancer groups significeantly varied （P〈 0. 01 ） to control group. Conclusion PAI -1 maybe can used as a auxiliary marker to detect cancer and PAI-I can be a potential target for tumor therapy.

关 键 词：纤溶酶原激活物抑制剂1 癌症 血浆 标志物 

分 类 号：R730.4[医药卫生—肿瘤]